Clinical roundup: new data from Gilead, Sagimet, Ionis, Novartis and BMS
Gilead falls on Trodelvy readout; plus Sagimet’s value-driving NASH data, and updates from Ionis, Novartis and BMS
Though a negative readout in second-line lung cancer evaporated more than $11 billion of its market cap on Monday, Gilead Sciences Inc. (NASDAQ:GILD) believes there may remain a path forward for Trodelvy sacituzumab govitecan in a patient subgroup evaluated in the study, and the company remains optimistic that the antibody-drug conjugate will succeed in a separate trial’s first-line population.
Gilead said Trodelvy missed the primary endpoint in the Phase III EVOKE-01 study, failing to show an overall survival benefit in non-small cell lung cancer patients whose disease had progressed after treatment with chemotherapy and a checkpoint inhibitor. News of the study’s failure resulted in the company’s shares dropping 10% during Monday’s session...